OHE at ISPOR’s 20th Annual European Congress in Glasgow

Meet OHE researchers in Glasgow, where they’ll be presenting their work at ISPOR from 4th-8th November 2017

Next week, Glasgow will host the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress. OHE researchers will be in attendance and presenting OHE research.

The theme for this year’s Congress is The Evolution of Value in Health Care; a subject central to many of OHE’s research projects. We’ll be participating in 11 different sessions across 4 days, on a variety of topics including MCDA, EQ-5D, orphan drugs, antibiotics, and societal preferences.

Here’s a run-through (in chronological order) of what we’re involved in. Come and see us at one of our sessions.

Sunday 5th November

• 08:00-12:00: Risk-sharing / performance-based arrangements for drugs and other medical products.

With Lou Garrison and Josh Carlson of the University of Washington, Adrian Towse will be presenting on this intermediate-level short course. The course covers both theory and practice, including several examples of performance-based schemes from Europe, the United States, and Australia.

• 13:00-17:00: Using multi-criteria decision analysis in health care decision making: approaches & applications.

With Maarten IJzerman and Kevin Marsh, Martina Garau will present on this short course. The course provides an introduction to MCDA for health care. Martina’s presentation will focus on the use of MCDA in HTA, by reviewing current uses of MCDA for HTA and the challenges they pose.

Monday 6th November

• 12:45-13:45: PCN219: Is willingness to pay higher for cancer prevention and treatment?

This poster by Koonal Shah examines whether society is willing to pay more for cancer prevention and treatment than for other types of health care. It is based on a paper published in the Journal of Cancer Policy, which appeared in the ‘Value and Cancer’ special issue.

• 15:45-16:45: W5: Sustainable funding and fair pricing for orphan drugs: what are the solutions?

Martina Garau will lead a discussion with Michael Drummond, Saskia Knies and Olivier Ponet. The purpose of the workshop is to discuss options to make paying for orphan drugs sustainable for healthcare systems, whilst providing a ‘fair’ reward to manufacturers investing in areas of high unmet need but small populations. Martina will start the session providing evidence on the rate of HTA approval and reimbursement of orphan drugs across Europe, building on earlier work.

• 15:45-16:45: IP6: Are existing health technology assessment requirements inadequate for establishing value for potentially transformative gene therapies?

For this issue panel, Adrian Towse will share his perspective on approaches to evaluating the cost-effectiveness of gene therapies, considering the high up-front costs and potential longer-term and/or transformative benefits, building on work with the Institute for Clinical and Economic Review (ICER) and presented at the ICER Gene Therapy Summit.

Tuesday 7th November

• 08:45-09:45: W10: EQ-5D: Is NICE ready for the next level?

Nancy Devlin (representing the EuroQol Research Foundation), Rosemary Lovett and Allan Wailoo will lead a discussion of why the EQ-5D-5L was developed, the evidence for its advantages over the EQ-5D-3L, and ongoing research into the characteristics of the valuation sets.

• 14:00-15:00: IP12: What should patient-centred care mean in the welfare states of Europe? The United Kingdom and Germany cannot both be right.

Nancy Devlin joins Axel Mühlbacher for a panel discussion.

• 15:30-16:30: IP13: MCDA valuation and ICERs – can they align for decision-making purposes?

Nancy Devlin will join this invited issue panel, which will debate and discuss the merits of approaches to comparing costs and benefits in the context of multi-criteria decision analysis (MCDA) models.

• 18:15-19:15: PHP195: Valuing health at the end of life: an examination of framing effects and study design considerations.

This poster, presented by Koonal Shah, assesses whether any observed preferences regarding an end-of-life premium are affected by framing effects, such as whether or not visual aids and indifference options are included in the survey. The study used a six-arm design, with each arm applying a different framing.

Koonal Shah and Nancy Devlin are co-authors of two other posters in this session, which report findings from the EQ-5D-5L value set for Ireland study, led by researchers at NUI Galway. These posters will be presented by Luke Barry and Anna Hobbins. Patricia Cubi-Molla co-authors a poster titled ‘Patients acknowledge adaptation: the case of amputees’.

Wednesday 8th November

• 10:00-11:00: IP22: How can we assess the value of new antibiotics?

Adrian Towse will present work from the OHE on developing a value framework for antibiotics, building on a recent Discussion Forum in London with key stakeholders.

• 15:30-16:30: IP27: Valuing children’s HRQoL for health technology assessment: what are the issues and challenges?

Nancy Devlin will be moderating this issue panel.